Tabrizi, Sarah J. http://orcid.org/0000-0003-2716-2045
Flower, Michael D.
Ross, Christopher A.
Wild, Edward J. http://orcid.org/0000-0002-6921-7887
Article History
Accepted: 29 June 2020
First Online: 14 August 2020
Competing interests
: In the past two years S.J.T. has undertaken consultancy services, including advisory boards, with F. Hoffmann-La Roche Ltd, Ixitech Technologies, Takeda Pharmaceuticals International and Triplet therapeutics. All honoraria for these consultancies were paid to University College London, S.J.T.’s employer. Through the offices of UCL Consultants Ltd, a wholly owned subsidiary of University College London, S.J.T. has undertaken consultancy services for Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, GSK, Heptares Therapeutics, LoQus therapeutics, Takeda Pharmaceuticals Ltd, TEVA Pharmaceuticals, Triplet therapeutics, UCB Pharma S.A., University College Irvine and Vertex Pharmaceuticals Incorporated. S.J.T. receives grant funding for her research from Takeda Pharmaceuticals and Cantervale Limited. C.A.R. is chair of the Research Advisory Board of the Huntington Study Group. Within the past two years, C.A.R. has consulted for Annexon, Roche, Sage and uniQure. C.A.R. receives funding for Huntington disease research from F. Hoffman-La Roche. Through UCL Consultants Ltd, a wholly owned subsidiary of University College London. E.J.W. has served on scientific advisory boards for F. Hoffmann–La Roche, Ionis, Mitoconix, Novartis, PTC Therapeutics, Shire, Takeda Pharmaceuticals and Wave Life Sciences. M.D.F. declares no competing interests.